149 related articles for article (PubMed ID: 29115604)
1. Genetically engineered recombinant adenovirus expressing interleukin‑2 for hepatocellular carcinoma therapy.
Sun Y; Wu H; Chen G; Huang X; Shan Y; Shi H; Zhang Q; Zheng Y
Mol Med Rep; 2018 Jan; 17(1):300-306. PubMed ID: 29115604
[TBL] [Abstract][Full Text] [Related]
2. Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy.
Bai F; Niu Z; Tian H; Li S; Lv Z; Zhang T; Ren G; Li D
Immunol Lett; 2014; 159(1-2):36-46. PubMed ID: 24613899
[TBL] [Abstract][Full Text] [Related]
3. An autologous in situ tumor vaccination approach for hepatocellular carcinoma. 2. Tumor-specific immunity and cure after radio-inducible suicide gene therapy and systemic CD40-ligand and Flt3-ligand gene therapy in an orthotopic tumor model.
Kawashita Y; Deb NJ; Garg MK; Kabarriti R; Fan Z; Alfieri AA; Roy-Chowdhury J; Guha C
Radiat Res; 2014 Aug; 182(2):201-10. PubMed ID: 24992166
[TBL] [Abstract][Full Text] [Related]
4. Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1/CD137L Subverts the Suppression of CD8
Zhang Y; Zhang H; Wei M; Mou T; Shi T; Ma Y; Cai X; Li Y; Dong J; Wei J
Mol Ther; 2019 Nov; 27(11):1906-1918. PubMed ID: 31466933
[TBL] [Abstract][Full Text] [Related]
5. Recombinant Newcastle Disease Virus Encoding IL-12 and/or IL-2 as Potential Candidate for Hepatoma Carcinoma Therapy.
Ren G; Tian G; Liu Y; He J; Gao X; Yu Y; Liu X; Zhang X; Sun T; Liu S; Yin J; Li D
Technol Cancer Res Treat; 2016 Oct; 15(5):NP83-94. PubMed ID: 26303327
[TBL] [Abstract][Full Text] [Related]
6. Gene therapy by membrane-expressed superantigen for alpha-fetoprotein-producing hepatocellular carcinoma.
Si S; Sun Y; Li Z; Ge W; Zhang X; Hu P; Huang Y; Chen G; Song H; Huang Y; Ma B; Li X; Sui Y
Gene Ther; 2006 Nov; 13(22):1603-10. PubMed ID: 16855617
[TBL] [Abstract][Full Text] [Related]
7. Local delivery of recombinant adenovirus expressing hepatitis B virus X protein and interleukin-12 results in antitumor effects via inhibition of hepatoma cell growth and intervention of tumor microenvironment.
He H; Fan P; Yin T; Chen Q; Shi H; Liu S; Li H; Jing Q; Yan Y; Zhang H; Yang L; Wen Y; Li Y; Cheng P
Int J Mol Med; 2012 Sep; 30(3):599-605. PubMed ID: 22710287
[TBL] [Abstract][Full Text] [Related]
8. [Antitumor effect of gene therapy with recombinant adenovirus-mediated human interleukin-2 gene transfer and its mechanism].
Du J; Ran Y; Lin Z; Zheng C; Wei H; Wang X; Zhou L; Ren Y
Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Jan; 34(1):12-5. PubMed ID: 15600167
[TBL] [Abstract][Full Text] [Related]
9. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.
Gao H; Li K; Tu H; Pan X; Jiang H; Shi B; Kong J; Wang H; Yang S; Gu J; Li Z
Clin Cancer Res; 2014 Dec; 20(24):6418-28. PubMed ID: 25320357
[TBL] [Abstract][Full Text] [Related]
10. The effects of interleukin 2 and rAd-p53 as a treatment for glioblastoma.
Qiao HB; Li J; Lv LJ; Nie BJ; Lu P; Xue F; Zhang ZM
Mol Med Rep; 2018 Mar; 17(3):4853-4859. PubMed ID: 29328445
[TBL] [Abstract][Full Text] [Related]
11. An autologous in situ tumor vaccination approach for hepatocellular carcinoma. 1. Flt3 ligand gene transfer increases antitumor effects of a radio-inducible suicide gene therapy in an ectopic tumor model.
Kawashita Y; Deb NJ; Garg M; Kabarriti R; Alfieri A; Takahashi M; Roy-Chowdhury J; Guha C
Radiat Res; 2014 Aug; 182(2):191-200. PubMed ID: 24972258
[TBL] [Abstract][Full Text] [Related]
12. Gene therapy with CX3CL1/Fractalkine induces antitumor immunity to regress effectively mouse hepatocellular carcinoma.
Tang L; Hu HD; Hu P; Lan YH; Peng ML; Chen M; Ren H
Gene Ther; 2007 Aug; 14(16):1226-34. PubMed ID: 17597794
[TBL] [Abstract][Full Text] [Related]
13. Autophagy enhances antitumor immune responses induced by irradiated hepatocellular carcinoma cells engineered to express hepatitis B virus X protein.
Yan Y; Liu N; Lu L; Zang CM; Shao B; Li Y; Wen Y; Wei Y; Cheng P
Oncol Rep; 2013 Aug; 30(2):993-9. PubMed ID: 23754319
[TBL] [Abstract][Full Text] [Related]
14. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
[TBL] [Abstract][Full Text] [Related]
15. Gene Therapy for Hepatocellular Carcinoma Using Adenoviral Vectors Delivering a Gene Encoding IL-17A-Neutralizing Antibody Fragments.
Zou H; Tuhin IJ; Monty MA; Luo S; Shao J; Yan Z; Yu L
Hum Gene Ther; 2020 Oct; 31(19-20):1074-1085. PubMed ID: 32390483
[TBL] [Abstract][Full Text] [Related]
16. Enhanced specific antitumor immunity of dendritic cells transduced with the glypican 3 gene and co-cultured with cytokine-induced killer cells against hepatocellular carcinoma cells.
Wang Y; Wang Y; Mu H; Liu T; Chen X; Shen Z
Mol Med Rep; 2015 May; 11(5):3361-7. PubMed ID: 25625609
[TBL] [Abstract][Full Text] [Related]
17. Improving immunotherapy of hepatocellular carcinoma (HCC) using dendritic cells (DC) engineered to express IL-12 in vivo.
Vogt A; Sievers E; Lukacs-Kornek V; Decker G; Raskopf E; Meumann N; Büning H; Sauerbruch T; Strassburg CP; Schmidt-Wolf IG; Gonzalez-Carmona MA
Liver Int; 2014 Mar; 34(3):447-61. PubMed ID: 23998316
[TBL] [Abstract][Full Text] [Related]
18. Targeted Hsp70 expression combined with CIK-activated immune reconstruction synergistically exerts antitumor efficacy in patient-derived hepatocellular carcinoma xenograft mouse models.
Hu H; Qiu Y; Guo M; Huang Y; Fang L; Peng Z; Ji W; Xu Y; Shen S; Yan Y; Huang X; Zheng J; Su C
Oncotarget; 2015 Jan; 6(2):1079-89. PubMed ID: 25473902
[TBL] [Abstract][Full Text] [Related]
19. Promising therapeutic efficacy of a novel reduced expression in immortalized cells/dickkopf-3 expressing adenoviral vector for hepatocellular carcinoma.
Sawahara H; Shiraha H; Uchida D; Kato H; Kato R; Oyama A; Nagahara T; Iwamuro M; Horiguchi S; Tsutsumi K; Mandai M; Mimura T; Wada N; Takeuchi Y; Kuwaki K; Onishi H; Nakamura S; Watanabe M; Sakaguchi M; Takaki A; Nouso K; Yagi T; Nasu Y; Kumon H; Okada H
J Gastroenterol Hepatol; 2017 Oct; 32(10):1769-1777. PubMed ID: 28168749
[TBL] [Abstract][Full Text] [Related]
20. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U
Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
